Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

nycomed gmbh - ciklesonid - inhalationsspray, lösning - 160 mikrogram/dos - ciklesonid 0,16 mg aktiv substans; etanol, vattenfri hjälpämne - ciklesonid

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

nycomed gmbh - ciklesonid - inhalationsspray, lösning - 80 mikrogram/dos - ciklesonid 0,08 mg aktiv substans; etanol, vattenfri 4,456 mg aktiv substans - ciklesonid

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

takeda pharma ab - ciklesonid - inhalationsspray, lösning - 40 mikrogram/dos - etanol, vattenfri hjälpämne; ciklesonid 0,04 mg aktiv substans - ciklesonid

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

nycomed gmbh - ciklesonid - inhalationsspray, lösning - 40 mikrogram/dos - etanol, vattenfri 4,456 mg aktiv substans; ciklesonid 0,04 mg aktiv substans - ciklesonid

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

nycomed gmbh - ciklesonid - inhalationsspray, lösning - 40 mikrogram/dos - etanol, vattenfri 4,456 mg aktiv substans; ciklesonid 0,04 mg aktiv substans - ciklesonid

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

nycomed gmbh - ciklesonid - inhalationsspray, lösning - 80 mikrogram/dos - etanol, vattenfri hjälpämne; ciklesonid 0,08 mg aktiv substans - ciklesonid

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

sandoz a/s - budesonid; formoterolfumaratdihydrat - inhalationspulver, avdelad dos - 160 mikrogram/4,5 mikrogram/inhalation - laktitolmonohydrat hjälpämne; budesonid 160 mikrog aktiv substans; formoterolfumaratdihydrat 4,5 mikrog aktiv substans

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

sandoz a/s - budesonid; formoterolfumaratdihydrat - inhalationspulver, avdelad dos - 320 mikrogram/9 mikrogram/inhalation - laktosmonohydrat hjälpämne; formoterolfumaratdihydrat 9 mikrog aktiv substans; budesonid 320 mikrog aktiv substans

Uniunea Europeană - suedeză - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - läkemedel mot obstruktiv lungsjukdom, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Uniunea Europeană - suedeză - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - läkemedel mot obstruktiv lungsjukdom, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).